 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2023, vol. 29, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2023294.5188
Published online: 26 October 2023
Original article
J of IMAB. 2023 Oct-Dec;29(4):5188-5191
OVERALL AND CANCER-SPECIFIC SURVIVAL OF HIGH-RISK PROSTATE CANCER – IMPACT OF ADJUVANT THERAPY AFTER RADICAL PROSTATECTOMY
Tosho Ganev
,
Clinic of Urology, Department of Surgery, Faculty of Medicine, MHAT "Sveta Anna", Medical University-Varna, Bulgaria.
ABSTRACT:
Purpose: The study examines the survival of patients with high-risk prostate cancer in order to find a relationship between survival and the type of postoperative therapy.
Materials/Methods: The object of the study were 872 patients who underwent radical prostatectomy in the Clinic of Urology in "St. Anna - Varna" Hospital for the period from April 17, 1996, until November 25, 2022. Postoperatively, some patients were additionally subjected to hormonal therapy (referred to as "dual therapy" in the text), and others to hormonal and radiotherapy (referred to as "triple therapy").
Results: Overall and cancer-specific survival of high-risk patients did not differ statistically significantly for the two types of postoperative therapy.
Conclusions: The optimal combination of radical prostatectomy, hormonal and radiotherapy in order to achieve maximum survival for patients with high-risk prostate cancer is still poorly defined.
Keywords: hormonal therapy, radiotherapy, Gleason score,
- Download FULL TEXT /PDF 725 KB/
Please cite this article as: Ganev T. Overall and cancer-specific survival of high-risk prostate cancer – impact of adjuvant therapy after radical prostatectomy. J of IMAB. 2023 Oct-Dec;29(4):5188-591. [Crossref - 10.5272/jimab.2023294.5188]
Correspondence to: Tosho Ganev, Department of surgery, MHAT "Sveta Anna-Varna", Clinic of Urology, Medical University-Varna; 100, Tzar Osvoboditel Blvd., Varna 9000, Bulgaria; E-mail: dr_ganev@yahoo.com
REFERENCES:
1. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun;173(6):1938-42. [PubMed]
2. Donohue JF, Bianco FJ Jr, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006 Sep;176(3):991-5. [PubMed]
3. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23;299(3):289-95. [PubMed]
4. Bolla M. The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach. Eur Urol. 2012 Aug;62(2):220-1; author reply 222-3. [PubMed]
5. Lazarov B. [Application of the ISUP classification in the analysis of patients with prostate carcinoma.] [in Bulgarian] Clinical urology. 2022; 2(1):5-9. [Internet]
6. Lazarov B. Factors predicting a possible increase of Gleason score after radical prostatectomy in patients with well-differentiated prostate cancer. Trakia Journal of Sciences. 2022; 20(2):146-151. [Crossref]
7. Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, et al. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 Feb;3(1):10-20. [PubMed]
8. Lazarov B. [The relationship between PSA and Gleason score in prostate cancer patients: our clinical experience.] [in Bulgarian] Varna Medical Forum. 2023; 12(1)147-150. [Crossref]
9. Preisser F, Tilki D. [Multimodal treatment of high-risk and locally advanced prostate cancer.] [in German] Urologie. 2022 Dec;61(12):1341-1344. [PubMed]
10. Rozet F, Audenet F, Sanchez-Salas R, Galiano M, Barret E, Cathelineau X. Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer. Expert Rev Anticancer Ther. 2013 Jul;13(7):811-8. [PubMed]
11. Lazarov B. [Analysis of biochemical progression-free survival of patients undergoing radical prostatectomy at MHAT "St. Anna-Varna".] [in Bulgarian] Clinical urology. 2022; 2(3):11-15. [Internet].
Received: 15 May 2023
Published online: 26 October 2023